Abigail Lang
Our proposed project will seek to determine if an oral medication called zileuton, which blocks the synthesis of inflammatory molecules called leukotrienes that are involved in allergic reactions, may be able to decrease absorption of food allergens and prevent severe food allergy reactions from occurring. Our study will measure levels of peanut in the blood before and after subjects consume an allergen they can tolerate and compare the results with and without administration of the study medication, zileuton. If our study shows that zileuton can decrease the absorption of a food allergen, this will allow us to see if this medication can be used to prevent anaphylaxis to food. The goal of this proof-of-concept study is to determine whether zileuton inhibits food allergen absorption in children and adolescents with food allergy. The main questions it aims to answer are: * Does zileuton administration impact food allergen absorption in children and adolescents with food allergies? * What is the variability of food allergen absorption in children and adolescents with IgE-mediated food allergies? Researchers will compare levels of peanut allergen proteins in the participants' blood with and without a dose of zileuton prior to a test meal of peanut protein. * Visit 1 will involve a baseline blood draw, a test meal of peanut protein and a post-meal blood draw. * Visit 2 will involve a baseline blood draw, a dose of zileuton before the test meal of peanut protein, and blood draws after the test meal.
Inclusion Criteria: * Adolescent subjects ages 12-17 * Parent or guardian fluent in English * Known IgE-mediated food allergy other than peanut * Confirmed by clinical history of reaction to the food antigen plus 1. positive skin prick testing and/or serum food-specific IgE AND 2. confirmation of the food allergy diagnosis by a board-certified allergist Exclusion Criteria: * A previous positive peanut specific IgE test or skin prick test, or a history of any allergic symptoms following peanut consumption * Medical conditions known to affect the gastrointestinal tract * Any histo…
Zileuton is available in 600 mg strength yellow-colored oval tablets. A single dose of 1200 mg zileuton ER (two 600 mg zileuton tablets) will be administered to each participant.